Studies Add Validity to Cannabis' Medical Capabilities
All over the world, the debate over cannabis' ability to replace traditional medicines goes on as more medicinal applications continue to emerge. A handful of countries have already adopted medical cannabis programs due to the positive results of multiple extensive studies, while others, however, still remain on the fence. Nevertheless, countries such as Australia, Canada, France, Germany, and large swathes of the U.S. have already implemented medicinal cannabis legislation. According to Healthline, marijuana, a derivative of the cannabis plant, has been used to treat chronic pain as far back as 2900 B.C. However, international government bodies classified cannabis and its derivatives as a narcotic due to the psychoactive effects caused by its THC compound. In order to overturn the classification, medical institutions and researchers have begun conducting clinical trials to evaluate the efficacy of the plant and its chemical components. Now, scientists have discovered that certain components of the cannabis plant, such as CBD and THC, are heavily linked to the successful treatment of a variety of medical conditions. The human body contains a biological system dubbed the endocannabinoid system which is connected to biological functions such as sleep, appetite, pain, and the immune system response. The human body naturally produces these endocannabinoids, which are neurotransmitters that bind to cannabinoid receptors in the nervous system. As a result, studies have shown that cannabinoids can effectively suppress pain, stimulate appetite, or alleviate depression. Currently, the medical cannabis sector accounts for the majority of the global cannabis market because of its widespread adoption. However, researchers have suggested that a larger shift from medical to recreational cannabis is expected to occur as countries like Canada and the U.S. ramp up their adult-use programs. Nonetheless, despite the ongoing development within the recreational market, medical cannabis will continue to be more readily available and accessible to consumers around the globe. According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 14.5 Billion in 2018. By 2024, the market is projected to reach USD 89.1 Billion while exhibiting a CAGR of 37% during the forecast period from 2019 to 2024. Trutrace Technologies Inc. (OTC: BKKSF) (TSX-V: TTT), India Globalization Capital, Inc. (NYSE-A: IGC), Auxly Cannabis Group Inc. (OTC: CBWTF) (TSX-V: XLY), InMed Pharmaceuticals, Inc. (OTC: IMLFF) (TSX: IN), Invictus MD Strategies Corp. (OTC: IVITF) (TSX-V: GENE)
Consumer Access to CBD Products Grows as National Retailers Stock Shelves
After the U.S. Farm Bill passed, CBD-based products have sprung up across the entire country. U.S. President Donald Trump signed the bill into effect in late 2018 after witnessing immense support pouring in from states. Shortly afterward, retailers across the country began to sell CBD products. Now, consumers can easily find CBD products such as oils, tinctures, and edibles at their local convenience stores and even pharmacies. According to the National Conference of State Legislatures, 41 states have so far set up cultivation and production programs to regulate the production of hemp. Cowen, an investment bank and financial services company, noted that in 2018, CBD retail sales were between USD 600 Million and USD 2 Billion. By 2025, Cowen projects that CBD sales will reach the USD 16 Billion mark. Major corporations such as CVS, Walgreens, Amazon, and Sephora have all began to distribute CBD products in their stores. And Cowen believes that the health and wellness category is expected to account for a majority of CBD sales. Specifically, Cowen projects that nutraceuticals will account for USD 6.4 Billion in sales while topicals are estimated to deliver USD 4 Billion in sales. Other segments such as food, beverages, beauty, and vapor are expected to generate combined sales of USD 1 to USD 1.25 Billion by 2025. Despite the CBD marketplace's rapid expansion, it is still heavily hindered by the lack of clinical trials and research. Despite this, the U.S. Food and Drug Administration still approved the first CBD-based treatment: Epidiolex, adding yet more credibility to the compound's function. Moreover, many cannabis companies have clinical trials underway in order to assess and evaluate CBD treatments for seizure disorders. NutraLife Biosciences, Inc. (OTC: NLBS), India Globalization Capital, Inc. (NYSE-A: IGC), The Supreme Cannabis Company (OTC: SPRWF) (TSX: FIRE), Terra Tech Corp. (OTC: TRTC), Invictus MD Strategies Corp. (OTC: IVITF) (TSX-V: GENE)
Invictus Announces Appointment of Director and Chief Operating Officer
VANCOUVER , May 9, 2019 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) the Company is pleased to announce the appointment of Trevor Dixon as a Director and Chief Operating Officer of the Company effective immediately. Mr. Dixon is the founder, President and Chief Executive Officer of the Company's wholly owned subsidiary Acreage Pharms Ltd. (" Acreage Pharms ").